Recurrent pure mucinous carcinoma of the breast with mediastinal great vessel invasion: HER-2/neu confers aggressiveness

American Surgeon

Volumn 74, Issue 2, 2008, Pages 113-116

  Adair, Jamie D ^a   Harvey, Kyle P ^a   Ali, Mahmood ^a   Caralis, James ^a   Gordon, William ^a   Yanish, Gregory ^a  

^a ST JOSEPH MERCY OAKLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; TRASTUZUMAB;

ADULT; AGGRESSIVENESS; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; BREAST TUMOR; CANCER INVASION; CASE REPORT; FEMALE; GREAT BLOOD VESSEL; HUMAN; LYMPH NODE DISSECTION; MASTECTOMY; MEDIASTINUM; MUCINOUS CARCINOMA; PALPATION; PREMENOPAUSE; RECURRENT CANCER; THORAX WALL; TRANSVERSE RECTUS ABDOMINIS MUSCULOCUTANEOUS FLAP;

ADENOCARCINOMA, MUCINOUS; ADULT; BRACHIOCEPHALIC VEINS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MEDIASTINUM; NEOPLASM INVASIVENESS; NEOPLASMS, SECOND PRIMARY; VASCULAR NEOPLASMS; VENA CAVA, SUPERIOR;

EID: 40949124256     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Li C, Moe R, Daling J. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 2003;163:2149-53.
2. Northridge ME, Rhoads GG, Wartenberg D, et al. The importance of histologic type on breast cancer survival. J Clin Epidemiol 1997;50:283-90.
3. Norris HJ, Taylor HB. Prognosis of mucinous (gelatinous) carcinoma of the breast. Cancer 1965;18:879-85.
4. Rosen PP, Wang TY. Colloid carcinoma of the breast: Analysis of 64 patients with long term follow up. Am J Clin Pathol 1980;73:304.
5. Diab S, Clark G, Osborne K, et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol 1999;17:1442.
6. Fentiman IS, Millis RR, Smith P, et al. Mucoid breast carcinomas: Histology and prognosis. Br J Cancer 1997;75:1061-5.
7. Silverberg SG, Kay S, Chitale AR, Levitt SH. Colloid carcinoma of the breast. Am J Clin Path. 1971;55:355-63.
8. Ishikawa T, Hamaguchi Y, Ichikawa Y, et al. Local advanced mucinous carcinoma of the breast with sudden growth acceleration: A case report. Jpn J Clin Oncol 2002;32:64-7.
9. Rasmussen BB, Rose C, Christensen IB. Prognostic factors in primary mucinous breast carcinoma. Am J Clin Path 1987;87:155-60.
10. Toikkanen S, Kujari H. Pure and mixed mucinous carcinomas of the breast: A clinicopathologic analysis of 61 cases with long-term follow-up. Hum Pathol 1989;20:758-64.
11. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1238-9.
12. Menard S, Fortis S, Castiglioni F, et al. HER-2 as a prognostic factor in breast cancer. Oncology 2001;61(suppl 2):67-72.
13. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-28.
14. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
15. Lam WW, Chu WC, Tse GM, et al. Role of fine needle aspiration and tru cut biopsy in diagnosis of mucinous carcinoma of the breast - from a radiologist's perspective. Clin Imaging 2006;30:6-10.
16. Stanford School of Medicine Surgical Pathology Criteria. Pure mucinous carcinoma of the breast. 2007 Stanford University School of Medicine; available at http://surgpathcriteria.stanford.edu/breast/mucincabr/index.html.
17. Slamon DJ, Leyland-Jones B, Shak S, et al. Concurrent administration of anti-HER-2 monoclonal antibody and first line chemotherapy for HER-2 overexpressing metastatic breast cancer: A phase III, multinational, randomized control trial. N Engl J Med 2001;783:792.